Follow On Biologic



Recombinant humanized anti-IL-17A monoclonal antibody injections, potential indications include psoriasis, psoriatic arthritis, ankylosing spondylitis. QX002N is the first new drug in our country with completely independent intellectual property rights. In April 2019, IND application was approved for clinical development, and in June of the same year, the first phase clinical trial was initiated.